logo
  

Swiss Re Proposes Vanessa Lau, Pia Tischhauser As Board Members

Reinsurer Swiss Re Ltd. (SSREY.PK) Friday said its Board of Directors will nominate Vanessa Lau and Pia Tischhauser for election as new members at the upcoming Annual General Meeting of shareholders on April 12, 2023.

The current Board members Renato Fassbind and Susan L. Wagner will not stand for re-election.

Vanessa Lau is the Group Chief Financial Officer of Hong Kong Exchanges and Clearing Limited. Pia Tischhauser served on the Executive Committee of Boston Consulting Group as an elected member from 2016 to end 2021.

The company noted that Fassbind has served on Swiss Re's Board of Directors since 2011 and will reach the 12-year tenure limit at the AGM. He is the Vice Chairman and Lead Independent Director of the Board, and also chairs the Audit Committee and is a member of the Governance and Nomination Committee and the Compensation Committee.

Wagner has 9-years of service on Swiss Re's Board of Directors. She chairs the Investment Committee, is a member of the Governance and Nomination Committee and was a member of the Finance and Risk Committee for many years.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Health insurer Humana Inc. reported Wednesday a net loss for the fourth quarter that slightly widened from last year, hurt primarily by charges associated with productivity initiatives, despite 6.6 percent revenue growth. Adjusted earnings for the quarter topped analysts' expectations, while quarterly revenues missed it by a whisker. South Plainfield, New Jersey-based Two Rivers Coffee is recalling its peanut butter single serve hot chocolate pods citing an undeclared peanut allergen, the U.S. Food Drug Administration said. The recall involves peanut butter single serve hot chocolate pods distributed as "Brooklyn Bean Peanut Butter Cup Hot Cocoa", "Pingo Peanut Butter Cookie Hot Chocolate" and ... Shares of Novartis AG were losing around 2 percent in the early morning trading in Switzerland after the drug major reported Wednesday sharply lower profit in its fourth quarter with weak sales as well as the absence of prior year's hefty Roche income. Adjusted earnings, however, topped market estimates, while top line missed their view. Further, the company announced higher dividend...
Follow RTT